科兴制药(688136) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of 140,675.89 million yuan, representing a year-on-year increase of 11.73%[3]. - The net profit attributable to the parent company was 3,153.15 million yuan, a significant turnaround from a loss of 19,029.03 million yuan in the previous year[3]. - The basic earnings per share increased to 0.16 yuan from a loss of 0.96 yuan in the previous year[3]. - The weighted average return on net assets improved to 1.94%, an increase of 13.05 percentage points compared to the previous year[3]. - Total assets at the end of the reporting period were 316,190.03 million yuan, up 4.32% from the beginning of the period[3]. Cost Management - The company effectively controlled operating costs, leading to a decrease in sales, research and development, and production costs[7]. Revenue Sources - The significant growth in overseas revenue was driven by sales of paclitaxel albumin in the EU region[7]. Non-Recurring Gains and Losses - Non-recurring gains and losses were positively impacted by government subsidies and changes in the fair value of private equity funds held by the company[8]. - The company is currently awaiting the audit report and final valuation of its private equity fund, which may affect its non-recurring gains and losses for 2024[9]. Financial Reporting - The financial data presented is preliminary and subject to final confirmation in the annual report[2].